Work

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

Year: 2015

Type: editorial

Abstract: RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.

Source: Molecular & Cellular Oncology

DOI: 10.1080/23723556.2015.1048405

Authors: Leanne G. Ahronian, Ryan B. Corcoran

Institutions: Harvard University, Massachusetts General Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,590